CERo Therapeutics Holdings, Inc. announced that it has entered into the the Securities Purchase Agreement with certain accredited investors that it has issued 12,580 shares of Series A convertible preferred stock, par value $0.0001 per share of the company, warrants to purchase 125,000 shares of Common Stock and warrants to purchase 2,000 shares of Series A Preferred Stock for the aggregate gross proceeds of $9,400,000 on February 14, 2024. Concurrent with the consummation of the PIPE financing, the company entered into a registration rights agreement with the PIPE Investors, pursuant to which the company agreed to provide the PIPE Investors with customary registration rights related to the shares issued under the Securities Purchase Agreement.
The company has raised $10,193,654 from 46 investors pursuant to regulation D.